• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

新型冠状病毒肺炎康复者血浆高抗体滴度列线图的研制

Development of a nomogram for high antibody titre of COVID-19 convalescent plasma.

作者信息

Wang Shichun, Yan Jie, Song Min, Xue Zhenrui, Wang Zerong, Diao Ronghua, Liu Qi, Ruan Qianying, Yao Chunyan

机构信息

Department of Blood Transfusion, First Affiliated Hospital, Third Military Medical University (Army Medical University), Chongqing, P.R. China.

State Key Laboratory of Trauma and Chemical Poisoning, Third Military Medical University, Chongqing, P.R China.

出版信息

Epidemiol Infect. 2024 Dec 11;152:e167. doi: 10.1017/S0950268824001638.

DOI:10.1017/S0950268824001638
PMID:39659202
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11696598/
Abstract

This study aimed to develop a predictive tool for identifying individuals with high antibody titers crucial for recruiting COVID-19 convalescent plasma (CCP) donors and to assess the quality and storage changes of CCP. A convenience sample of 110 plasma donors was recruited, of which 75 met the study criteria. Using univariate logistic regression and random forest, 6 significant factors were identified, leading to the development of a nomogram. Receiver operating characteristic curves, calibration plots, and decision curve analysis (DCA) evaluated the nomogram's discrimination, calibration, and clinical utility. The nomogram indicated that females aged 18 to 26, blood type O, receiving 1 to 2 COVID-19 vaccine doses, experiencing 2 symptoms during infection, and donating plasma 41 to 150 days after symptom onset had higher likelihoods of high antibody titres. Nomogram's AUC was 0.853 with good calibration. DCA showed clinical benefit within 9% ~ 90% thresholds. CCP quality was qualified, with stable antibody titres over 6 months ( > 0.05). These findings highlight developing predictive tools to identify suitable CCP donors and emphasize the stability of CCP quality over time, suggesting its potential for long-term storage.

摘要

本研究旨在开发一种预测工具,用于识别具有高抗体滴度的个体,这对于招募新冠康复期血浆(CCP)捐献者至关重要,并评估CCP的质量和储存变化。招募了110名血浆捐献者的便利样本,其中75名符合研究标准。使用单因素逻辑回归和随机森林,确定了6个显著因素,从而开发出一种列线图。通过受试者工作特征曲线、校准图和决策曲线分析(DCA)评估列线图的辨别力、校准度和临床效用。列线图显示,年龄在18至26岁之间的女性、O型血、接种1至2剂新冠疫苗、感染期间出现2种症状以及在症状出现后41至150天捐献血浆的个体,具有较高抗体滴度的可能性更大。列线图的曲线下面积(AUC)为0.853,校准良好。DCA显示在9%至90%的阈值范围内具有临床益处。CCP质量合格,抗体滴度在6个月内稳定(>0.05)。这些发现突出了开发预测工具以识别合适的CCP捐献者的重要性,并强调了CCP质量随时间的稳定性,表明其具有长期储存的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/da86c7a34cca/S0950268824001638_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/b42fd344fd5e/S0950268824001638_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/bb63e32aeb4e/S0950268824001638_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/05b2c0d08c84/S0950268824001638_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/ab66ff1d0f08/S0950268824001638_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/da86c7a34cca/S0950268824001638_fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/b42fd344fd5e/S0950268824001638_fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/bb63e32aeb4e/S0950268824001638_fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/05b2c0d08c84/S0950268824001638_fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/ab66ff1d0f08/S0950268824001638_fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/17b3/11696598/da86c7a34cca/S0950268824001638_fig5.jpg

相似文献

1
Development of a nomogram for high antibody titre of COVID-19 convalescent plasma.新型冠状病毒肺炎康复者血浆高抗体滴度列线图的研制
Epidemiol Infect. 2024 Dec 11;152:e167. doi: 10.1017/S0950268824001638.
2
Blood group O convalescent plasma donations have significantly lower levels of SARS-CoV-2 IgG antibodies compared to blood group A donations.与 A 型血捐献者相比,O 型血恢复期血浆捐献者的 SARS-CoV-2 IgG 抗体水平显著较低。
Transfusion. 2021 Aug;61(8):2245-2249. doi: 10.1111/trf.16524. Epub 2021 May 27.
3
Association between clinical symptoms during the COVID-19 infection and SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors in China.中国 COVID-19 恢复期全血献血者在 COVID-19 感染期间的临床症状与 SARS-CoV-2 免疫球蛋白 G 滴度之间的关系。
Transfusion. 2024 Jun;64(6):1025-1039. doi: 10.1111/trf.17843. Epub 2024 Apr 25.
4
Feasibility of a pilot program for COVID-19 convalescent plasma collection in Wuhan, China.中国武汉 COVID-19 恢复期血浆采集试点项目的可行性。
Transfusion. 2020 Aug;60(8):1773-1777. doi: 10.1111/trf.15921. Epub 2020 Jul 31.
5
Use of Outpatient-Derived COVID-19 Convalescent Plasma in COVID-19 Patients Before Seroconversion.COVID-19 患者在出现血清转换之前使用门诊获得的 COVID-19 恢复期血浆。
Front Immunol. 2021 Sep 14;12:739037. doi: 10.3389/fimmu.2021.739037. eCollection 2021.
6
Screening for SARS-CoV-2 antibodies in convalescent plasma in Brazil: Preliminary lessons from a voluntary convalescent donor program.巴西恢复期血浆中 SARS-CoV-2 抗体筛查:一项自愿恢复期供者计划的初步经验教训。
Transfusion. 2020 Dec;60(12):2938-2951. doi: 10.1111/trf.16065. Epub 2020 Sep 16.
7
Early, very high-titre convalescent plasma therapy in clinically vulnerable individuals with mild COVID-19: an international, randomised, open-label trial.在患有轻度新型冠状病毒肺炎(COVID-19)的临床易感个体中进行早期、高滴度恢复期血浆治疗:一项国际随机开放标签试验
EBioMedicine. 2025 Mar;113:105613. doi: 10.1016/j.ebiom.2025.105613. Epub 2025 Feb 27.
8
Outpatient COVID-19 convalescent plasma recipient antibody thresholds correlated to reduced hospitalizations within a randomized trial.在一项随机试验中,门诊新冠康复期血浆接受者的抗体阈值与住院率降低相关。
JCI Insight. 2024 Mar 14;9(8):e178460. doi: 10.1172/jci.insight.178460.
9
Characteristics of coronavirus disease 19 convalescent plasma donors and donations in the New York metropolitan area.纽约都会区 2019 冠状病毒病康复期血浆捐献者和捐献的特点。
Transfusion. 2021 Aug;61(8):2374-2383. doi: 10.1111/trf.16421. Epub 2021 May 4.
10
Predictors of high SARS-CoV-2 immunoglobulin G titers in COVID-19 convalescent whole-blood donors: a cross-sectional study in China.新冠肺炎恢复期全血献血者高 SARS-CoV-2 免疫球蛋白 G 滴度的预测因素:中国的一项横断面研究。
Front Immunol. 2023 Jun 14;14:1191479. doi: 10.3389/fimmu.2023.1191479. eCollection 2023.

本文引用的文献

1
Simple prediction of COVID-19 convalescent plasma units with high levels of neutralization antibodies.用高滴度中和抗体简单预测 COVID-19 恢复期血浆单位。
Virol J. 2023 Mar 27;20(1):53. doi: 10.1186/s12985-023-02007-0.
2
Convalescent plasma (hyperimmune immunoglobulin) for COVID-19 management: An update.用于COVID-19治疗的康复期血浆(高免疫球蛋白):最新情况
Process Biochem. 2023 Apr;127:66-81. doi: 10.1016/j.procbio.2023.01.018. Epub 2023 Jan 31.
3
From past to future: Bibliometric analysis of global research productivity on nomogram (2000-2021).
从过去到未来:全球nomogram 研究生产力的文献计量分析(2000-2021 年)。
Front Public Health. 2022 Sep 20;10:997713. doi: 10.3389/fpubh.2022.997713. eCollection 2022.
4
ABO blood group and link to COVID-19: A comprehensive review of the reported associations and their possible underlying mechanisms.ABO 血型与 COVID-19 的关联:对已报道关联的综合回顾及其可能的潜在机制。
Microb Pathog. 2022 Aug;169:105658. doi: 10.1016/j.micpath.2022.105658. Epub 2022 Jun 25.
5
Emergency Use of Convalescent Plasma: Perception of the Regulatory Framework from a Clinical Perspective.恢复期血浆的紧急使用:从临床角度看监管框架
Transfus Med Hemother. 2021 Nov 15;49(2):119-124. doi: 10.1159/000519841. eCollection 2022 Apr.
6
Inactivated Vaccines Against SARS-CoV-2: Neutralizing Antibody Titers in Vaccine Recipients.针对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的灭活疫苗:疫苗接种者的中和抗体滴度
Front Microbiol. 2022 Mar 10;13:816778. doi: 10.3389/fmicb.2022.816778. eCollection 2022.
7
Early Outpatient Treatment for Covid-19 with Convalescent Plasma.Covid-19 的早期门诊康復期血浆治疗。
N Engl J Med. 2022 May 5;386(18):1700-1711. doi: 10.1056/NEJMoa2119657. Epub 2022 Mar 30.
8
The (apparent) antibody paradox in COVID-19.新冠病毒抗体悖论(明显的)。
Expert Rev Clin Immunol. 2022 Apr;18(4):335-345. doi: 10.1080/1744666X.2022.2044797. Epub 2022 Mar 10.
9
Robust validation and performance comparison of immunogenicity assays assessing IgG and neutralizing antibodies to SARS-CoV-2.评估针对 SARS-CoV-2 的 IgG 和中和抗体的免疫原性检测方法的稳健验证和性能比较。
PLoS One. 2022 Feb 7;17(2):e0262922. doi: 10.1371/journal.pone.0262922. eCollection 2022.
10
Antibody response against SARS-CoV-2 in convalescent plasma donors: Can we predict subjects' eligibility?康复期血浆捐献者对严重急性呼吸综合征冠状病毒2(SARS-CoV-2)的抗体反应:我们能否预测受试者的合格性?
Hematol Transfus Cell Ther. 2022 Jan-Mar;44(1):1-6. doi: 10.1016/j.htct.2021.07.008. Epub 2021 Nov 4.